You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
|
---|---|
Published in |
Neuro-Oncology, April 2020
|
DOI | 10.1093/neuonc/noaa107 |
Pubmed ID | |
Authors |
Carmen Balana, Maria Angeles Vaz, Juan Manuel Sepúlveda, Carlos Mesia, Sonia del Barco, Estela Pineda, Jose Muñoz-Langa, Anna Estival, Ramón de las Peñas, Jose Fuster, Regina Gironés, Luis Miguel Navarro, Miguel Gil-Gil, Miriam Alonso, Ana Herrero, Sergio Peralta, Clara Olier, Pedro Perez-Segura, Maria Covela, Maria Martinez-García, Alfonso Berrocal, Oscar Gallego, Raquel Luque, Franciso Javier Perez-Martín, Anna Esteve, Nuria Munne, Marta Domenech, Salvador Villa, Carolina Sanz, Cristina Carrato |
X Demographics
The data shown below were collected from the profiles of 139 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 26 | 19% |
United States | 23 | 17% |
United Kingdom | 11 | 8% |
Germany | 5 | 4% |
Colombia | 3 | 2% |
Mexico | 3 | 2% |
India | 2 | 1% |
Canada | 2 | 1% |
Brazil | 2 | 1% |
Other | 10 | 7% |
Unknown | 52 | 37% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 90 | 65% |
Scientists | 25 | 18% |
Practitioners (doctors, other healthcare professionals) | 23 | 17% |
Science communicators (journalists, bloggers, editors) | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 73 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 7 | 10% |
Researcher | 6 | 8% |
Student > Ph. D. Student | 5 | 7% |
Student > Postgraduate | 5 | 7% |
Student > Doctoral Student | 4 | 5% |
Other | 17 | 23% |
Unknown | 29 | 40% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 24 | 33% |
Biochemistry, Genetics and Molecular Biology | 5 | 7% |
Nursing and Health Professions | 2 | 3% |
Unspecified | 2 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 1% |
Other | 5 | 7% |
Unknown | 34 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 96. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 December 2023.
All research outputs
#447,252
of 25,591,967 outputs
Outputs from Neuro-Oncology
#47
of 3,556 outputs
Outputs of similar age
#13,984
of 406,392 outputs
Outputs of similar age from Neuro-Oncology
#2
of 73 outputs
Altmetric has tracked 25,591,967 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,556 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,392 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 73 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.